SI-BONE(US:SIBN)2022-01-21 19:50Market Opportunity & Leadership - The company addresses a large market with a $2.5 billion annual U S opportunity[7] - The company has pioneered sacropelvic surgical solutions, with approximately 65,000 procedures performed worldwide using iFuse Technology[7, 21, 82] - The company estimates a majority U S market share with iFuse[7] Clinical & Technological Advantages - The company has over 35 exclusive payor policies and approximately 160 million U S exclusive covered lives[7, 8, 21, 68, 82] - The company's iFuse demonstrates 6x resistance compared to SI screws[33] - The company's iFuse demonstrates 3x strength compared to standard 8 0mm cannulated screws[33] - The company's iFuse-3D shows 57-point improvement in VAS Pain Reduction and 25-point improvement in ODI Disability[47] Financial Performance & Growth - The company anticipates record FY21 revenue of $89 8 - $90 1 million, representing a year-over-year growth of 22-23%[63, 70, 75] - The company maintains a strong annual gross margin between 87% and 89%[61, 71] - The company has approximately $146 million in cash and equivalents as of December 31, 2021[75]